Literature DB >> 14760084

Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro.

Lisa G Horvath1, Susan M Henshall, James G Kench, Darren N Saunders, C-Soon Lee, David Golovsky, Phillip C Brenner, Gordon F O'Neill, Raji Kooner, Phillip D Stricker, John J Grygiel, Robert L Sutherland.   

Abstract

PURPOSE: Activation of the Wnt-signaling pathway is implicated in aberrant cellular proliferation in a variety of cancers. Secreted frizzled-related protein 4 (sFRP4) is a secreted protein with putative inhibitory activity of the Wnt-signaling cascade through binding and sequestering Wnt ligands. Because sFRP4 mRNA is overexpressed in prostate cancers (PCs), the aim of this study was to define the pattern of sFRP4 protein expression in normal and malignant human prostate tissue and to determine whether changes in expression were associated with disease progression and prognosis, as well as to define the phenotype of sFRP4-overexpression in an in vitro model of PC. EXPERIMENTAL
DESIGN: Polyclonal antibodies were raised against a COOH-terminal peptide of sFRP4, characterized and used to assess sFRP4 protein expression in benign prostate tissue and 229 patients with clinically localized PC (median follow-up 77 months, range 1-156). In vitro studies of the function of sFRP4 overexpression were performed using PC3 cells transfected with sFRP4.
RESULTS: Benign and malignant prostate tissue demonstrated cytoplasmic sFRP4 immunoreactivity, but there was a decrease in the expression of membranous sFRP4 in PCs compared with the hyperplastic lesions (P < 0.0001). Kaplan-Meier analysis revealed that patients whose PC expressed membranous sFRP4 in >20% of cells had improved relapse-free survival compared with those with </=20% membranous expression (P = 0.002). Moreover, membranous sFRP4 expression (P = 0.04) was an independent predictor of relapse when modeled with Gleason score (P = 0.006), pathological stage (P = 0.002), and pre-operative prostate-specific antigen levels (P = 0.004). In addition, in vitro studies demonstrated a decrease in the proliferation rate of PC3 cells transfected with sFRP4 when compared with the control PC3-empty vector cells (P < 0.0001). Decreased levels of phosphorylated glycogen synthase kinase 3beta in PC3-sFRP4 cells suggested that this phenotype is mediated by the "Wnt/beta-catenin" pathway.
CONCLUSIONS: These data suggest that sFRP4 expression may be prognostic for localized PC, potentially as a consequence of an inhibitory effect on PC cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14760084     DOI: 10.1158/1078-0432.ccr-0707-03

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

1.  Wnt antagonist gene polymorphisms and renal cancer.

Authors:  Hiroshi Hirata; Yuji Hinoda; Koichi Nakajima; Nobuyuki Kikuno; Soichiro Yamamura; Kazumori Kawakami; Yutaka Suehiro; Z Laura Tabatabai; Nobuhisa Ishii; Rajvir Dahiya
Journal:  Cancer       Date:  2009-10-01       Impact factor: 6.860

2.  DNA hypermethylation of sFRP5 contributes to indoxyl sulfate-induced renal fibrosis.

Authors:  Yanlin Yu; Xu Guan; Ling Nie; Yong Liu; Ting He; Jiachuan Xiong; Xinli Xu; Yan Li; Ke Yang; Yiqin Wang; Yunjian Huang; Bing Feng; Jingbo Zhang; Jinghong Zhao
Journal:  J Mol Med (Berl)       Date:  2017-05-15       Impact factor: 4.599

Review 3.  Wnt/β-catenin signalling in prostate cancer.

Authors:  Robert M Kypta; Jonathan Waxman
Journal:  Nat Rev Urol       Date:  2012-06-19       Impact factor: 14.432

Review 4.  Secreted frizzled-related protein 4 and its implications in cancer and apoptosis.

Authors:  Sebastian Pohl; Ross Scott; Frank Arfuso; Vanathi Perumal; Arun Dharmarajan
Journal:  Tumour Biol       Date:  2014-12-13

5.  Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas.

Authors:  Ivan Martinez; Jun Wang; Kenosha F Hobson; Robert L Ferris; Saleem A Khan
Journal:  Eur J Cancer       Date:  2006-10-31       Impact factor: 9.162

Review 6.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

7.  An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.

Authors:  Alison Y Zhang; Karen Chiam; Ygal Haupt; Stephen Fox; Simone Birch; Wayne Tilley; Lisa M Butler; Karen Knudsen; Clay Comstock; Krishan Rasiah; Judith Grogan; Kate L Mahon; Tina Bianco-Miotto; Carmela Ricciardelli; Maret Böhm; Susan Henshall; Warick Delprado; Phillip Stricker; Lisa G Horvath; James G Kench
Journal:  Int J Cancer       Date:  2018-12-04       Impact factor: 7.396

8.  Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma.

Authors:  Pascal Gelebart; Mona Anand; Hanan Armanious; Anthea C Peters; Jennifer Dien Bard; Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2008-09-11       Impact factor: 22.113

9.  Antagonizing canonical Wnt signaling pathway by recombinant human sFRP4 purified from E. coli and its implications in cancer therapy.

Authors:  Archita Ghoshal; Siddhartha Sankar Ghosh
Journal:  Mol Cell Biochem       Date:  2016-06-23       Impact factor: 3.396

10.  Involvement of tazarotene-induced gene 1 in proliferation and differentiation of human adipose tissue-derived mesenchymal stem cells.

Authors:  S Ohnishi; K Okabe; H Obata; K Otani; S Ishikane; H Ogino; S Kitamura; N Nagaya
Journal:  Cell Prolif       Date:  2009-02-24       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.